Eton Pharmaceuticals, Inc. (ETON)
NASDAQ: ETON · IEX Real-Time Price · USD
3.140
-0.050 (-1.57%)
At close: Apr 17, 2024, 4:00 PM
3.060
-0.080 (-2.55%)
After-hours: Apr 17, 2024, 4:05 PM EDT
Company Description
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases.
The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.
It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Eton Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Nov 13, 2018 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 30 |
| CEO | Sean E. Brynjelsen |
Contact Details
Address: 21925 W. Field Parkway, Suite 235 Deer Park, Illinois 60010-7278 United States | |
| Phone | (847) 787-7361 |
| Website | etonpharma.com |
Stock Details
| Ticker Symbol | ETON |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001710340 |
| CUSIP Number | 29772L108 |
| ISIN Number | US29772L1089 |
| Employer ID | 37-1858472 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sean E. Brynjelsen | President, Chief Executive Officer and Director |
| James R. Gruber CPA | Chief Financial Officer, Treasurer and Secretary |
| David C. Krempa | Chief Business Officer |
| Ingrid Hoos | Senior Vice President of Regulatory Affairs |
| Kevin Guthrie | Executive Vice President of Commercial Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 26, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 22, 2024 | 10-K/A | [Amend] Annual report |
| Mar 22, 2024 | 8-K | Current Report |
| Mar 14, 2024 | 10-K | Annual Report |
| Mar 14, 2024 | 8-K | Current Report |
| Feb 21, 2024 | 8-K | Current Report |
| Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 2, 2024 | 8-K | Current Report |
| Nov 9, 2023 | 10-Q | Quarterly Report |
| Nov 9, 2023 | 8-K | Current Report |